COO
The Cooper Companies, Inc.$77.21
Sell
Target $58.93
Report: Feb 21, 2026Healthcare • Medical - Instruments & Supplies • Mature CompounderSnapshot
Decision-first overview with recommendation, valuation anchor, and current setup.
Company Overview
Research Snapshot
Price History
Pelican View
Current$77.21-23.7%
Rec: SellConviction: Low
Entry Target
N/A
N/A
Fair Value
$58.93
(24% below current)
Stop Loss
N/A
N/A
Position Size
None
Time Horizon
N/A
Key Metrics
Live Snapshot
Market Data
52 Week High$89.83
52 Week Low$61.78
Avg. 3 Month Volume2.07M
Efficiency
LTM Gross Margin65.4%
LTM EBITDA Margin27.2%
LTM EBIT Margin16.9%
LTM Operating Margin16.8%
LTM ROA3.2%
LTM ROE4.8%
LTM ROIC8.6%
LTM ROCE6.3%
Capital Structure
Market Cap (MM)$14.0B
Enterprise Value (MM)$16.3B
Shares Outstanding195.80M
Total Debt (MM)$2.50B
Cash & Equivalents (MM)$124.90M
LTM Net Debt (MM)$2.37B
LTM Net Debt/EBITDA2.1x
Growth
TTM Rev. Growth5.7%
Last 3-Yr Rev. CAGR7.1%
Last 3-Yr EBITDA CAGR6.4%
Last 3-Yr EPS CAGR2.2%
Valuation
Street Target Price$93.86
LTM EV/Revenue3.9x
LTM EV/Gross Profit6.0x
LTM EV/EBIT23.3x
LTM EV/EBITDA14.5x
LTM P/E34.8x
LTM EV/FCF33.2x
LTM P/FCF28.4x
LTM P/TB2.0x
LTM P/B1.7x
Dividend Yield0.0%
Payout Ratio0.0%
Executive SummarySituation: Current price is $77.21 versus fair value $58.93 (-23.7% expected return), and valuation confidence is stable. Debate: Bull case depends on Conclusion of the Strategic Review Management is currently evaluating 'all options' for the business structure. Bear case centers on Moat Erosion in Asia-Pacific Low-cost competitors and e-commerce pricing in Japan are aggressively taking share from Cooper's legacy hydrogel products, forcing a faster-than-expected mix shift to lower-margin daily lenses. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.
Bull Case
Accelerated adoption of MiSight myopia management lenses (23% growth) and the completion of the MyDay capacity expansion cycle could drive a re-acceleration of FCF; strong insider alignment evidenced by $2.52 million in net purchases.
Bear Case
Persistent margin compression from 18.1% to 16.3% and an 8.1% ROIC that fails to cover the 9.5% WACC; significant legal exposure from the CooperSurgical embryo culture media recall and genetic testing class actions.
Key Catalysts
Near-Term (0-6 months)Impact: Critical
Conclusion of the Strategic Review Management is currently evaluating 'all options' for the business structure. A failure to announce a tran...
Mid-Term (6-18 months)Impact: High
MyDay Capacity Ramp Completion The completion of the multi-year CapEx cycle should theoretically lift FCF. If margins fail to expand as capa...
Long-Term (18+ months)Impact: Moderate
This company is relevant for analysis now because it is trading near its 52-week high despite deteriorating fundamentals, and the strategic...
Primary Risks
Concern: High
Moat Erosion in Asia-Pacific Low-cost competitors and e-commerce pricing in Japan are aggressively taking share from Cooper's legacy hydroge...
Concern: Medium
Fertility Segment Litigation CooperSurgical faces a class action regarding recalled embryo culture media that allegedly destroyed human embr...
Concern: Medium
The governance structure is currently in a state of flux due to the active proxy pressure. We outline the following Governance Outcome Tree:...
Recent Activity
2025-12-05SEC Filing (8-K)
+5.67%Excerpt: Source: Attachment (EX-99.1) Document PRESS RELEASE Cooper Companies Announces Fourth Quarter and Full Year 2025 Results San Ramon, Calif., December 4, 2025 — Cooper Companies (Nasdaq: COO), a leading global medical device...
2025-08-28SEC Filing (8-K)
-12.86%Excerpt: Source: Attachment (EX-99.1) Document PRESS RELEASE Cooper Companies Announces Third Quarter 2025 Results San Ramon, Calif., August 27, 2025 — Cooper Companies (Nasdaq: COO), a leading global medical device company, today...
2025-05-30SEC Filing (8-K)
-14.61%Excerpt: Source: Attachment (EX-99.1) Document PRESS RELEASE Cooper Companies Announces Second Quarter 2025 Results San Ramon, Calif., May 29, 2025 — Cooper Companies (Nasdaq: COO), a leading global medical device company, today announced...
2025-03-07SEC Filing (8-K)
-6.57%Excerpt: Source: Attachment (EX-99.1) Document PRESS RELEASE Cooper Companies Announces First Quarter 2025 Results San Ramon, Calif., March 6, 2025 — Cooper Companies (Nasdaq: COO), a leading global medical device company, today announced...
2024-08-29SEC Filing (8-K)
+11.84%Excerpt: Source: Attachment (EX-99.1) Document PRESS RELEASE Cooper Companies Announces Third Quarter 2024 Results San Ramon, Calif., August 28, 2024 — Cooper Companies (Nasdaq: COO), a leading global medical device company, today...
Valuation Table
9.8/10Decision Grade
Scenario Range
$35
Bear
$49
Base
$60
Bull
$77